Martina Kinzig‐Schippers

Should We Use <i>N</i> -Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses?

Martina Kinzig‐Schippers, Dorota Tomalik‐Scharte, Alexander Jetter et al. · Antimicrobial Agents and Chemotherapy · 2005 · 197 citations · Full text

Molecular Pharmacology, High-activity Nat2 Allele, Pharmacological Study +12

Toxicokinetics of Acrylamide in Humans after Ingestion of a Defined Dose in a Test Meal to Improve Risk Assessment for Acrylamide Carcinogenicity

Uwe Fuhr, Melanie I. Boettcher, Martina Kinzig‐Schippers et al. · Cancer Epidemiology Biomarkers & Prevention · 2006 · 179 citations

Defined Dose, Acrylamide Carcinogenicity, Dietary Exposure +14

Population Pharmacokinetics and Pharmacodynamics of Continuous versus Short-Term Infusion of Imipenem-Cilastatin in Critically Ill Patients in a Randomized, Controlled Trial

Samir G. Sakka, Anna K. Glauner, Jürgen B. Bulitta et al. · Antimicrobial Agents and Chemotherapy · 2007 · 152 citations · Full text

Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers

Wolfgang A. Krueger, Jürgen B. Bulitta, Martina Kinzig‐Schippers et al. · Antimicrobial Agents and Chemotherapy · 2005 · 102 citations · Full text

Effects of grapefruit juice on the pharmacokinetics of sildenafil

Alexander Jetter, Martina Kinzig‐Schippers, Monika Walchner‐Bonjean et al. · Clinical Pharmacology & Therapeutics · 2002 · 84 citations